CN1162160C - Low-condensing agent universal freeze-dried blood plasma - Google Patents
Low-condensing agent universal freeze-dried blood plasma Download PDFInfo
- Publication number
- CN1162160C CN1162160C CNB021373973A CN02137397A CN1162160C CN 1162160 C CN1162160 C CN 1162160C CN B021373973 A CNB021373973 A CN B021373973A CN 02137397 A CN02137397 A CN 02137397A CN 1162160 C CN1162160 C CN 1162160C
- Authority
- CN
- China
- Prior art keywords
- blood plasma
- type
- condensing agent
- plasma
- freeze
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to the technical field of blood products and low-condensing agent universal freeze-dried blood plasma which is suitable for transfusion for patients of four blood types of A, B, O, AB. Because the mixture ratio of four types of blood plasma of A, B, O and AB of the existing universal blood plasma, exsanguine universal freeze-dried blood plasma, etc. is not appropriate, especially, AB-type blood plasma is used minimumly or is not used, and therefore, the titer of a condensing agent of blood plasma is higher, and the possibility of initiating transfusion reaction exists. The present invention regulates the mixture ratio of plasma volume, enlarges the proportion of AB-type blood plasma and reduces or does not add AB-type blood plasma. O-type blood plasma, A-type blood plasma and B-type blood plasma are added with the same proportion, thereby, the titer of the condensing agent of universal blood plasma is reduced, both anti A and anti B are not more than 1:2, so the safety and validity of transfusion is ensured.
Description
Technical field: the present invention relates to the blood products technical field, is the low-condensing agent universal freeze-dried blood plasma that is suitable for A, B, the defeated usefulness of four kinds of blood group patients of AB, O.
Background technology: well-known, the application of blood plasma is comparatively general clinically.Usually to the blood plasma of the corresponding blood group of patient's infusion of different blood groups, this is not only made troubles because of the blood plasma of different blood groups stores respectively, and may incur loss through delay rescue opportunity to the critical patient because of before treatment, doing definite evaluation to patient's blood group, moreover, the blood plasma of single blood group is originated limited after all, just in case reserves are not enough, may jeopardize patient's life.So existing in recent years " universally applicable blood plasma " (application for a patent for invention prospectus, publication number CN1272061A, open day on November 1st, 2000), " freeze-dried plasma without blood group and preparation method thereof " (application for a patent for invention prospectus, publication number CN1321468A, open day November 14 calendar year 2001) report such as.Blood plasma that can be general can overcome the deficiency of typing blood plasma undoubtedly, and the storage of blood plasma and patient's rescue are brought convenience.It is all higher that yet above-mentioned " universally applicable blood plasma " and the agglutinin of the anti-A of " freeze-dried plasma without blood group ", anti-B are tired, and therefore has the probability that causes transfusion reaction, unfavorable to curing patient.Causing anti-A, the anti-B agglutinin high reason of tiring is to adopt the blended proportioning of various blood plasma suitable inadequately, especially few with or without AB type blood plasma, as " freeze-dried plasma without blood group ", its proportioning is: A type blood plasma 5-10 part, Type B blood plasma 2-7 part, O type blood plasma 0.5-3 part, AB type blood plasma 0.5-3 part, its agglutinin that mixes back blood plasma is tired and is anti-A≤1: 4-1: 8, and anti-B≤1: 8-1: 16.
Summary of the invention: tire minimum according to the anti-A of AB type blood plasma, anti-B agglutinin, the anti-A of O type blood plasma, the anti-B agglutinin the highest characteristics of tiring, the present invention adjusts the proportioning of four kinds of blood group blood plasma: the ratio that strengthens AB type blood plasma under possible condition, minimizing does not even add O type blood plasma, and A type and Type B blood plasma are by adding on year-on-year basis.Thereby can make the general frozen dry blood plasma that low agglutinin is tired, its anti-A≤1: 2, anti-B≤1: 2 can guarantee the safety of using.
The capacity ratio of four kinds of blood group blood plasma of the present invention is:
A type blood plasma 1-10 part, Type B blood plasma 1-10 part
O type blood plasma 0-5 part, AB type blood plasma 〉=10 parts
Wherein A, Type B blood plasma are by adding on year-on-year basis.
The optimum ratio of this programme is:
A type blood plasma 5-10 part, Type B blood plasma 5-10 part
O type blood plasma 0-5 part, AB type blood plasma 20-40 part
The preparation method of the general frozen dry blood plasma of the present invention is basic identical with the preparation method of above-mentioned " freeze-dried plasma without blood group ": the mixed that different shaped blood plasma is provided by the present invention, with S/D method inactivation of viruses, that is with 1%TNBP (tributyl phosphate) and 1%Tritonx-100 30 ℃ of insulations 4 hours, reuse vegetable oil extraction TNBP, the C18 reversed phase column chromatography is removed Tritonx-100, filtration, degerming packing, lyophilizing.Can contain medicinal stabilizing agent in the blood plasma, anticoagulant, whole process is not with protective agent.
The specific embodiment:
The preferred embodiment of the present invention is as shown in the table:
| Group | Various plasma volume proportioning (umber) | Agglutinin is tired | ||||
| The A type | Type B | The O type | The AB type | Anti-A | Anti-B | |
| 1 | 10 | 10 | 5 | 20 | 1∶2 | 1∶2 |
| 2 | 10 | 10 | 1 | 20 | 1∶1 | 1∶1 |
| 3 | 1 | 1 | 0 | 40 | 1∶1 | 1∶1 |
| 4 | 5 | 5 | 1 | 30 | 1∶1 | 1∶1 |
| 5 | 2 | 2 | 1 | 35 | 1∶1 | 1∶1 |
| 6 | 10 | 10 | 0 | 10 | 1∶1 | 1∶1 |
Advantage of the present invention and good effect be anti-A, anti-B agglutinin tire≤1: 2, guaranteed the safety and the effectiveness of the clinical use of universally applicable blood plasma of the present invention.
Claims (4)
1, low-condensing agent universal freeze-dried blood plasma is mixed by A type, Type B, O type, AB type blood plasma, it is characterized in that the capacity ratio of blood plasma is:
A type blood plasma 1-10 part, Type B blood plasma 1-10 part,
O type blood plasma 0-5 part, AB type blood plasma 10-40 part
Wherein A type blood plasma is identical with Type B blood plasma proportioning.
2, by the described low-condensing agent universal freeze-dried blood plasma of claim 1, it is characterized in that the capacity ratio of blood plasma is:
A type blood plasma 5-10 part, Type B blood plasma 5-10 part,
O type blood plasma 0-5 part, AB type blood plasma 20-40 part,
Middle A type is identical with the blood plasma proportioning of Type B.
3, by the described low-condensing agent universal freeze-dried blood plasma of claim 1, it is characterized in that the capacity ratio of blood plasma is:
10 parts of A type blood plasma, 10 parts of Type B blood plasma,
5 parts of O type blood plasma, 20 parts of AB type blood plasma.
4, by the described low-condensing agent universal freeze-dried blood plasma of claim 1, it is characterized in that the capacity ratio of blood plasma is:
10 parts of A type blood plasma, 10 parts of Type B blood plasma,
1 part of O type blood plasma, 20 parts of AB type blood plasma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021373973A CN1162160C (en) | 2002-10-11 | 2002-10-11 | Low-condensing agent universal freeze-dried blood plasma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021373973A CN1162160C (en) | 2002-10-11 | 2002-10-11 | Low-condensing agent universal freeze-dried blood plasma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1403094A CN1403094A (en) | 2003-03-19 |
| CN1162160C true CN1162160C (en) | 2004-08-18 |
Family
ID=4748985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021373973A Expired - Lifetime CN1162160C (en) | 2002-10-11 | 2002-10-11 | Low-condensing agent universal freeze-dried blood plasma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1162160C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11604026B2 (en) | 2019-03-14 | 2023-03-14 | Terumo Bct Biotechnologies, Llc | Lyophilization loading tray assembly and system |
| US11634257B2 (en) | 2017-10-09 | 2023-04-25 | Terumo Bct Biotechnologies, Llc | Lyophilization container and method of using same |
-
2002
- 2002-10-11 CN CNB021373973A patent/CN1162160C/en not_active Expired - Lifetime
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11634257B2 (en) | 2017-10-09 | 2023-04-25 | Terumo Bct Biotechnologies, Llc | Lyophilization container and method of using same |
| US11604026B2 (en) | 2019-03-14 | 2023-03-14 | Terumo Bct Biotechnologies, Llc | Lyophilization loading tray assembly and system |
| US11609043B2 (en) | 2019-03-14 | 2023-03-21 | Terumo Bct Biotechnologies, Llc | Lyophilization container fill fixture, system and method of use |
| US11609042B2 (en) | 2019-03-14 | 2023-03-21 | Terumo Bct Biotechnologies, Llc | Multi-part lyophilization container and method of use |
| US11740019B2 (en) | 2019-03-14 | 2023-08-29 | Terumo Bct Biotechnologies, Llc | Lyophilization loading tray assembly and system |
| US11747082B2 (en) | 2019-03-14 | 2023-09-05 | Terumo Bct Biotechnologies, Llc | Multi-part lyophilization container and method of use |
| US11815311B2 (en) | 2019-03-14 | 2023-11-14 | Terumo Bct Biotechnologies, Llc | Lyophilization container fill fixture, system and method of use |
| US11994343B2 (en) | 2019-03-14 | 2024-05-28 | Terumo Bct Biotechnologies, Llc | Multi-part lyophilization container and method of use |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1403094A (en) | 2003-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Carless et al. | Fibrin sealant use for minimising peri‐operative allogeneic blood transfusion | |
| Cicardi et al. | Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients | |
| Quick | Components of the prothrombin complex | |
| Vamvakas | Meta‐analysis of the studies of bleeding complications of platelets pathogen‐reduced with the Intercept system | |
| Lefer et al. | Mechanism of the protective effect of corticosteriods in hemorrhagic shock | |
| Schulz et al. | Unstimulated leukapheresis in patients and donors: comparison of two apheresis systems | |
| Li et al. | Non-continuous versus continuous wound drainage after total knee arthroplasty: a meta-analysis | |
| Rasouli et al. | Blood conservation | |
| CN1162160C (en) | Low-condensing agent universal freeze-dried blood plasma | |
| Lu et al. | Epsilon aminocaproic acid reduces blood transfusion and improves the coagulation test after pediatric open-heart surgery: a meta-analysis of 5 clinical trials | |
| Irsch et al. | Update on pathogen inactivation treatment of plasma, with the INTERCEPT Blood System: Current position on methodological, clinical and regulatory aspects | |
| Robert et al. | Rheopheresis: A new therapeutic approach in severe calciphylaxis | |
| CN1207004C (en) | Freeze-dried plasma without blood group and its preparation method | |
| CN1168455C (en) | Low agglutinin universal refrigerated plasma | |
| Song et al. | Mesenchymal stem cells, extracellular vesicles, and transcranial magnetic stimulation for ferroptosis after spinal cord injury | |
| WO2020211009A1 (en) | Use of extract from rabbit skin inflamed by vaccinia virus in treating hematopoietic system damage | |
| CN1215850C (en) | Fresh refrigerated plasma without blood group | |
| CN1488361A (en) | Low lectin general blood plasma | |
| Xiang et al. | Retrospective study of twenty-four patients with prolonged coagulopathy due to long-acting anti-vitamin K rodenticide poisoning | |
| Miatech et al. | Management of acquired factor VIII inhibitors with NovoSeven and obizur | |
| CN100368017C (en) | Compound bioogic component and pharmaceutical preparation possessing function for accelerating hemoglutination | |
| Drummond et al. | Management of a Jehovah's Witness with thrombotic thrombocytopaenic purpura/haemolytic uraemic syndrome | |
| Ibrahim et al. | Depression among Egyptian End Stage Renal Disease Patients Under Maintenance Hemodialysis. | |
| Hequet et al. | The first results demonstrating efficiency and safety of a double-column whole blood method of LDL-apheresis | |
| Vuylsteke et al. | Abdominal pain, hypertension, and thrombocytopenia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term |
Granted publication date: 20040818 |
|
| CX01 | Expiry of patent term |